Health and Me

Tanya Dutt

NHS Needs 1 Million Blood Donors To Prevent 'Red Alert' Emergency Shortage

The NHS has issued a nationwide appeal calling more than one million individuals in England to come forward and become routine blood donors. The urgent call to action follows the fact that blood supplies are reaching perilously low levels, jeopardizing the safety and security of hospital care throughout the nation. NHS Blood and Transplant (NHSBT), the body that oversees England's blood supply, cautions that if the gap in donors is not filled, there will be a "red alert"—a crisis level at which patient care is directly put at risk.

Fewer than 800,000 individuals, or only 2% of England's population, are currently keeping the nation's blood supply going. With demand increasing and supplies depleted as a result of emergencies, cyberattacks, and missed appointments, health authorities warn that this figure is no longer tenable.

A "red alert" level in blood supply control is one thing: hospitals can be forced to put off or cancel life-saving operations because inventory is perilously low. The UK has already had a July "amber alert," prompted by a cyberattack affecting London hospitals, which caused a substantial dislocation of logistics and demand. NHSBT reports that stocks have recovered somewhat since July but remain below levels of safe operation—especially for some key blood types.

O negative blood, or the universal donor type, is particularly in demand. It's the go-to in emergency cases when the patient's blood type is not known. Transported by air ambulances and utilized in trauma centers, it represents about 16% of hospital orders. Supplies of this type are currently critically low.

<h2>Why Black Donors Are Particularly Needed?</h2>

Another issue of urgency is a shortage of Black community blood donors. Black individuals are more likely to be rare blood types such as Ro, which is important to treat illnesses such as sickle cell disease—a hereditary condition disproportionately impacting individuals of African and Caribbean backgrounds.

NHSBT has always stressed the need for a diverse donor base, but improvement is slow. Even with rising campaigns, rates of donation from minority populations are failing to match medical demands. This disparity leaves patients with certain conditions at higher risk of complications, delayed treatment, or transfusion reaction due to unavailability of compatible blood.

The NHS drive to sign up one million regular donors is ambitious, but desirable. In 2024, an additional number of people signed up to become donors—but just 24% actually completed a donation. NHSBT considers a regular donor someone who gives blood at least once in a 12-month period. Which means most registered people aren't yet active members of the pool of blood contributors.

The process gets more alarming when taking into account how blood is utilized. About two-thirds of the blood collected is used to treat individuals who need continuous transfusions—patients with cancer, patients with blood diseases such as thalassemia or sickle cell, and patients receiving intricate surgeries.

Dr Jo Farrar, NHSBT Chief Executive, made a heartfelt plea to the public, saying, "If we had a million regular donors, it would keep our stocks healthy—you'd really be one in a million. Book an appointment today, feel good about saving lives, and come back and do it again a few months later."

This is supported in a plea by Health Minister Baroness Merron, who further added, "We are working with NHS Blood and Transplant to make giving blood simpler than ever before, opening new donor centres and making it possible to book appointments nearer home."

To increase participation, the NHS is expanding access to <span>blood donation</span> facilities and modernizing the booking process. Mobile blood drives, walk-in clinics, and new donor centres are being launched across cities and towns to reduce the friction between intention and action.

Both men and women are qualified to donate blood—men every three months and women every four months. The process is fast, safe, and can save as many as three lives per donation.

<h2>What Happens if There Is A Blood Shortage?</h2>

When blood levels drop into the red alert level, hospitals can be required to delay non-emergency procedures, limit access to routine transfusions, and ration patients by severity. These actions could result in preventable deaths and decreased health outcomes for thousands of people.

Previous incidents, the July 2024 amber alert for example, revealed how susceptible the system is to shock when something unforeseen—such as a cyberattack—shatters the equilibrium. In that instance, O negative inventory dropped to only 1.6 days' supply. A red alert would signal complete depletion.

The demand is obvious and imperative. Only 2% of individuals now bear the burden of a nation's blood supply. The NHS is calling on more citizens to volunteer and join a life-saving system that stretches across hospitals, accident and emergency departments, and ambulances.

Whether you're O negative, A positive, or another blood type entirely—your donation counts. Routine donors are the quiet healthcare heroes. Today is the day to become one.

Health Conditions A-Z

health

blood donation

nhs blood donor shortage

red alert blood supply

o negative blood crisis

uk blood donation 2025

sickle cell blood donors

nhsbt donation appeal

blood shortage england

Is It Just A Summer Cold Or The NB.1.8.1 Covid Variant? How To Tell When The Symptoms Are Nearly Identical

World’s First ‘Trojan Horse’ Blood Cancer Drug Rolled Out By NHS In England

Air India Crash May Have Triggered Flight Anxiety In Millions, Expert Shares How To Overcome Aerophobia

Health News

Common Mistakes You May Be Making While Working Out

Ways You Are Runing Your Weight Loss Journey

Beyond Fruits – How To Retain Hydration And Stay Safe In Summers

Can This Extremely Hot Weather Trigger Our Mental Health?

You Are Hurting Your Gut Health With These Habits

Avoid The Heat With These Indoor Exercises

Stay Sharp! Activities That Keep Cognitive Diseases At Bay

Protect Your Cardiovascular Health With These Heart Healthy Foods

Ways To Ease Nighttime Anxiety

Smoothie Ideas That Can Help With Weight Loss

Low Fat Foods That Are Actually Unhealthy

All Suryanamaskar Poses And How To Do Them

Do Changing Seasons Affect Your Weight?

Can Heatwave Affect Your Diet?

Heatwave To Monsoon: Health Concerns With Seasonal Changes

Standing Exercises That Help You Burn Calories

Reasons To Do Dancing As A Workout

Why Summer Fruits Are A Great Addition To Your Diet?

What Should You Avoid For Your Bladder?

Lower-Body Exercises For Strong Foundation

Healthy Drinks That Improve Your Digestion

World Tobacco Day: Unexpected Ways Smoking Can Affect You

Seasonal Mood Swings? How Weather Affects Mental Health

Is Calorie Counting Healthy? Dos And Don’ts

Heat-Related Illnesses That You Should Know

Menstrual Hygiene Day: Tips On Period Hygiene

​Add These High Protein Vegetarian Meals To Your Diet​

Top 10 Workouts That Burn Most Calorie

Makhana Season – Healthy &amp; Quick Foxnut Recipes

Monsoon Ahead – Tips On Building Rainy Season Immunity

Do You Have Prickly Heat Rash – Symptoms, Causes And Treatment

Healthy No-Cook Recipes You Can Try

How Do You Calorie Count – Numbers And Nutrients

Unexpected Signs Of Dehydration – Safety And Precaution Measures

Leg Exercises You Can Do At Home To Build Strength

Foods That Promote Skin Elasticity

Must-Do Chest Exercises You Can Try At Home

What Are The Symptoms Of JN.1 COVID-19 Strain?

Why Does Sleeping Become Harder As You Age?

High-Fiber Healthy Drinks You Should Try

The NHS has issued a nationwide appeal calling more than one million individuals in England to come forward and become routine blood donors. The urgent call to action follows the fact that blood supplies are reaching perilously low levels, jeopardizing the safety and security of hospital care throughout the nation. NHS Blood and Transplant (NHSBT), the body that oversees England's blood supply, cautions that if the gap in donors is not filled, there will be a "red alert"—a crisis level at which patient care is directly put at risk.Fewer than 800,000 individuals, or only 2% of England's population, are currently keeping the nation's blood supply going. With demand increasing and supplies depleted as a result of emergencies, cyberattacks, and missed appointments, health authorities warn that this figure is no longer tenable.A "red alert" level in blood supply control is one thing: hospitals can be forced to put off or cancel life-saving operations because inventory is perilously low. The UK has already had a July "amber alert," prompted by a cyberattack affecting London hospitals, which caused a substantial dislocation of logistics and demand. NHSBT reports that stocks have recovered somewhat since July but remain below levels of safe operation—especially for some key blood types.O negative blood, or the universal donor type, is particularly in demand. It's the go-to in emergency cases when the patient's blood type is not known. Transported by air ambulances and utilized in trauma centers, it represents about 16% of hospital orders. Supplies of this type are currently critically low.Why Black Donors Are Particularly Needed?Another issue of urgency is a shortage of Black community blood donors. Black individuals are more likely to be rare blood types such as Ro, which is important to treat illnesses such as sickle cell disease—a hereditary condition disproportionately impacting individuals of African and Caribbean backgrounds.NHSBT has always stressed the need for a diverse donor base, but improvement is slow. Even with rising campaigns, rates of donation from minority populations are failing to match medical demands. This disparity leaves patients with certain conditions at higher risk of complications, delayed treatment, or transfusion reaction due to unavailability of compatible blood.The NHS drive to sign up one million regular donors is ambitious, but desirable. In 2024, an additional number of people signed up to become donors—but just 24% actually completed a donation. NHSBT considers a regular donor someone who gives blood at least once in a 12-month period. Which means most registered people aren't yet active members of the pool of blood contributors.The process gets more alarming when taking into account how blood is utilized. About two-thirds of the blood collected is used to treat individuals who need continuous transfusions—patients with cancer, patients with blood diseases such as thalassemia or sickle cell, and patients receiving intricate surgeries.Dr Jo Farrar, NHSBT Chief Executive, made a heartfelt plea to the public, saying, "If we had a million regular donors, it would keep our stocks healthy—you'd really be one in a million. Book an appointment today, feel good about saving lives, and come back and do it again a few months later."This is supported in a plea by Health Minister Baroness Merron, who further added, "We are working with NHS Blood and Transplant to make giving blood simpler than ever before, opening new donor centres and making it possible to book appointments nearer home."To increase participation, the NHS is expanding access to blood donation facilities and modernizing the booking process. Mobile blood drives, walk-in clinics, and new donor centres are being launched across cities and towns to reduce the friction between intention and action.Both men and women are qualified to donate blood—men every three months and women every four months. The process is fast, safe, and can save as many as three lives per donation.What Happens if There Is A Blood Shortage?When blood levels drop into the red alert level, hospitals can be required to delay non-emergency procedures, limit access to routine transfusions, and ration patients by severity. These actions could result in preventable deaths and decreased health outcomes for thousands of people.Previous incidents, the July 2024 amber alert for example, revealed how susceptible the system is to shock when something unforeseen—such as a cyberattack—shatters the equilibrium. In that instance, O negative inventory dropped to only 1.6 days' supply. A red alert would signal complete depletion.The demand is obvious and imperative. Only 2% of individuals now bear the burden of a nation's blood supply. The NHS is calling on more citizens to volunteer and join a life-saving system that stretches across hospitals, accident and emergency departments, and ambulances.Whether you're O negative, A positive, or another blood type entirely—your donation counts. Routine donors are the quiet healthcare heroes. Today is the day to become one.

nhs needs 1 million blood donors to prevent 'red alert' emergency shortage

New Once-a-Week Pill May Transform Schizophrenia Treatment, Lancet Study Finds

new once-a-week pill may transform schizophrenia treatment, lancet study finds

Health & Wellness

Can You Get Cervical Cancer Without HPV?

can you get cervical cancer without hpv?

Smartphone Tool Can Now Detect Early Warning Signs Of Huntington’s Disease In 5 Minutes, Finds Study

smartphone tool can now detect early warning signs of huntington’s disease in 5 minutes, finds study

Blood Tests Could Reveal Cancer Cells 3 Years Before The Actual Diagnosis

blood tests could reveal cancer cells 3 years before the actual diagnosis

The England National Health Service (NHS) is the world's first healthcare system to offer a revolutionary <span>blood cancer</span> treatment called a "Trojan horse" drug. The trailblazing treatment, officially known as <span>belantamab mafodotin</span>, has the potential to add years to the lives of thousands of patients fighting multiple myeloma, a vicious and currently untreatable form of bone marrow cancer.

This innovation, now being rolled out to eligible patients throughout England, highlights the revolutionary promise of precision medicine and targeted treatments to change cancer care.

At the center of this medical innovation is belantamab mafodotin, also known as Blenrep and produced by GlaxoSmithKline. In contrast to traditional chemotherapy that gets into both healthy and cancer cells, this new medication uses a targeted approach: it binds to myeloma cells, enters them quietly, and delivers a fatal dose of chemotherapy directly within, effectively killing the malignancy from the inside out.

This "Trojan horse" metaphor comes from Greek mythology, as Greek warriors entered the city of Troy disguised within a wooden horse. In the same way, this drug corrupts cancer cells by smuggling a toxic payload into them disguised as an antibody—spared most healthy tissues in the process.

NHS England National Clinical Director for Cancer Professor Peter Johnson called the treatment "life-changing" and said, "Myeloma is an aggressive blood cancer, but the advent of belantamab mafodotin brings with it a new hope of highly extended disease control.

Multiple myeloma is a plasma cancer that arises in plasma cells present in the bone marrow. Although there are continued advances in medicine, the disease is still incurable and relapsing in nature. The majority of patients have a pattern of recurrence after remission, requiring multiple treatment lines.

Trials of belantamab mafodotin, particularly in combination with other drugs such as bortezomib and dexamethasone, have shown that the treatment can stop disease from progressing for a period of three years—three years longer than the 13-month postponement achieved with the drug of choice at present, daratumumab.

The National Institute for Health and Care Excellence (NICE), having checked the effectiveness and value for money, accelerated approval for the rollout of the treatment. NICE director Helen Knight stated, "This recommendation shows our determination to get patients the best treatment quickly while protecting value for the taxpayer." 

The NHS rollout will first address about 1,500 patients per year in England that have relapsed or are resistant to their existing treatments. These are often those with advanced myeloma who have run out of other standard treatments.

Significantly, this represents a move toward personalized, next-generation treatments being accessible through public healthcare facilities—an accomplishment welcomed by health activists and oncologists alike.

Shelagh McKinlay, Myeloma UK's Director of Research and Advocacy, hailed the announcement: "We have campaigned aggressively for the last year to get this drug approved. It will change the lives of thousands of myeloma patients."

Paul Silvester, who is 60 and from Sheffield, was diagnosed with multiple myeloma in 2023. When ordinary treatment and even a bone marrow transplant did not halt the disease, he was put on an early-access trial for belantamab mafodotin at the Royal Hallamshire Hospital.

The change was almost instant," he explained. "In the first two or three weeks following the first dose, I was in remission. I like to think this treatment has brought the party balloons into the house."

Paul is now in remission and mapping out history-themed travel excursions—something he never thought he'd ever be able to do a few months ago.

<h2>How Does Belantamab Mafodotin Work?</h2>

Belantamab mafodotin is an antibody-drug conjugate (ADC), a new class of cancer drugs. The drug's antibody component targets a protein (BCMA) on the outside of myeloma cells. After binding to the cancer cell, the complex is taken into the cell where it drops off a potent chemotherapy drug, essentially killing it from within.

This internal targeting results in much less collateral damage to normal cells—a major problem with standard chemotherapy—and decreases the overall treatment burden.

Although thought to be less toxic than many standard therapies, belantamab mafodotin is not without adverse effects. Patients can have dry eyes, blurred vision, and occasionally more severe ocular toxicity due to the mechanism of action of the drug leaking into surrounding tissues after cell kill.

Clinical teams are trained to monitor and manage these effects, often adjusting dosage or incorporating supportive therapies to preserve patient safety.

Health Minister Karin Smyth emphasized the significance of this development: “This groundbreaking therapy puts the NHS at the forefront of cancer innovation. By harnessing cutting-edge ‘Trojan horse’ technology, we’re offering new hope to blood cancer patients across the country.”

In fact, the move by the NHS to be the first healthcare system in the world to introduce this treatment establishes a precedent for the incorporation of high-cost, high-impact biologic therapies into national care.

With its effective implementation in England, belantamab mafodotin could soon be used as a worldwide standard of care for relapsed or refractory multiple myeloma. As other nations observe outcomes and cost-effectiveness trends, it is possible that health systems globally will look into implementing this Trojan horse technique.

Researchers in oncology are also looking at similar antibody-drug conjugates for other types of cancer, including breast, lung, and ovarian cancers—implying that we are just beginning to see what this technology has to give.

blood cancer

trojan horse cancer drug

belantamab mafodotin

multiple myeloma treatment

nhs blood cancer therapy

blenrep approval uk

antibody drug for myeloma

blood cancer breakthrough

The England National Health Service (NHS) is the world's first healthcare system to offer a revolutionary blood cancer treatment called a "Trojan horse" drug. The trailblazing treatment, officially known as belantamab mafodotin, has the potential to add years to the lives of thousands of patients fighting multiple myeloma, a vicious and currently untreatable form of bone marrow cancer.This innovation, now being rolled out to eligible patients throughout England, highlights the revolutionary promise of precision medicine and targeted treatments to change cancer care.How Does This Therapy Work?At the center of this medical innovation is belantamab mafodotin, also known as Blenrep and produced by GlaxoSmithKline. In contrast to traditional chemotherapy that gets into both healthy and cancer cells, this new medication uses a targeted approach: it binds to myeloma cells, enters them quietly, and delivers a fatal dose of chemotherapy directly within, effectively killing the malignancy from the inside out.This "Trojan horse" metaphor comes from Greek mythology, as Greek warriors entered the city of Troy disguised within a wooden horse. In the same way, this drug corrupts cancer cells by smuggling a toxic payload into them disguised as an antibody—spared most healthy tissues in the process.NHS England National Clinical Director for Cancer Professor Peter Johnson called the treatment "life-changing" and said, "Myeloma is an aggressive blood cancer, but the advent of belantamab mafodotin brings with it a new hope of highly extended disease control.Multiple myeloma is a plasma cancer that arises in plasma cells present in the bone marrow. Although there are continued advances in medicine, the disease is still incurable and relapsing in nature. The majority of patients have a pattern of recurrence after remission, requiring multiple treatment lines.Trials of belantamab mafodotin, particularly in combination with other drugs such as bortezomib and dexamethasone, have shown that the treatment can stop disease from progressing for a period of three years—three years longer than the 13-month postponement achieved with the drug of choice at present, daratumumab.The National Institute for Health and Care Excellence (NICE), having checked the effectiveness and value for money, accelerated approval for the rollout of the treatment. NICE director Helen Knight stated, "This recommendation shows our determination to get patients the best treatment quickly while protecting value for the taxpayer." Who Will Benefit?The NHS rollout will first address about 1,500 patients per year in England that have relapsed or are resistant to their existing treatments. These are often those with advanced myeloma who have run out of other standard treatments.Significantly, this represents a move toward personalized, next-generation treatments being accessible through public healthcare facilities—an accomplishment welcomed by health activists and oncologists alike.Shelagh McKinlay, Myeloma UK's Director of Research and Advocacy, hailed the announcement: "We have campaigned aggressively for the last year to get this drug approved. It will change the lives of thousands of myeloma patients."Paul Silvester, who is 60 and from Sheffield, was diagnosed with multiple myeloma in 2023. When ordinary treatment and even a bone marrow transplant did not halt the disease, he was put on an early-access trial for belantamab mafodotin at the Royal Hallamshire Hospital.The change was almost instant," he explained. "In the first two or three weeks following the first dose, I was in remission. I like to think this treatment has brought the party balloons into the house."Paul is now in remission and mapping out history-themed travel excursions—something he never thought he'd ever be able to do a few months ago.How Does Belantamab Mafodotin Work?Belantamab mafodotin is an antibody-drug conjugate (ADC), a new class of cancer drugs. The drug's antibody component targets a protein (BCMA) on the outside of myeloma cells. After binding to the cancer cell, the complex is taken into the cell where it drops off a potent chemotherapy drug, essentially killing it from within.This internal targeting results in much less collateral damage to normal cells—a major problem with standard chemotherapy—and decreases the overall treatment burden.Side Effects and Safety IssuesAlthough thought to be less toxic than many standard therapies, belantamab mafodotin is not without adverse effects. Patients can have dry eyes, blurred vision, and occasionally more severe ocular toxicity due to the mechanism of action of the drug leaking into surrounding tissues after cell kill.Clinical teams are trained to monitor and manage these effects, often adjusting dosage or incorporating supportive therapies to preserve patient safety.Health Minister Karin Smyth emphasized the significance of this development: “This groundbreaking therapy puts the NHS at the forefront of cancer innovation. By harnessing cutting-edge ‘Trojan horse’ technology, we’re offering new hope to blood cancer patients across the country.”In fact, the move by the NHS to be the first healthcare system in the world to introduce this treatment establishes a precedent for the incorporation of high-cost, high-impact biologic therapies into national care.With its effective implementation in England, belantamab mafodotin could soon be used as a worldwide standard of care for relapsed or refractory multiple myeloma. As other nations observe outcomes and cost-effectiveness trends, it is possible that health systems globally will look into implementing this Trojan horse technique.Researchers in oncology are also looking at similar antibody-drug conjugates for other types of cancer, including breast, lung, and ovarian cancers—implying that we are just beginning to see what this technology has to give.

world’s first ‘trojan horse’ blood cancer drug rolled out by nhs in england

Ishita Roy

RFK Hires Autism Skeptic To Look Into CDC Autism Data

RFK Hires Autism Skeptic

Kennedy Names New Vaccine Advisers Among Whom Are Anti-Vaxxers And Those Who Spread Misinformation

kennedy names new vaccine advisers among whom are anti-vaxxers and those who spread misinformation. after ousting the entire panel

Worried About The New And Dominant COVID Variant XEC? 3 Things You Must Know

worried about the new and dominant covid variant xec? 3 things you must know

COVID NB.1.8.1 Variant Triggers Extreme Throat Pain That Feels Like Swallowing 'Razor Blades'

covid nb.1.8.1 variant triggers extreme throat pain that feels like swallowing 'razor blades

is it just a summer cold or the nb.1.8.1 covid variant? how to tell when the symptoms are nearly identical

Dr. David Geier, a controversial orthopedic surgeon and known vaccine skeptic, is attempting to revisit long-debunked claims linking vaccines to autism. Recently hired by Health Secretary Robert F. Kennedy Jr., Geier is now reviewing historical safety data to investigate whether government agencies concealed crucial information.

<h4>Accessing <span rel="noindex">CDC</span>'s Vaccine Safety Database</h4>

Geier is reportedly seeking access to the U.S. Centers for Disease Control and Prevention’s (CDC) Vaccine Safety Datalink (VSD), a repository of vaccine safety records from millions of patients. The VSD is maintained by a dozen major healthcare systems, each controlling its own data. Full access has always been tightly controlled due to privacy and misuse concerns.

Geier previously accessed the database in 2004 and 2006. However, according to The Wall Street Journal, CDC officials revoked his access both times, alleging he had misrepresented his research intentions.

Despite this, Geier is once again pushing to analyze the data. It remains unclear if access has been granted. A spokesperson for the U.S. Department of Health and Human Services (HHS) stated that the department intends to take a “fresh look at all data including old data,” and emphasized that they would “follow the science—wherever it leads.”

<h4>Scientific Community Raises Concerns</h4>

The scientific and public health communities have expressed concern over Geier's involvement. “He has no record in the scientific community of doing valid work,” said Dr. Walter Orenstein, former director of the CDC’s immunization program.

Geier and his late father, geneticist Mark Geier, have long promoted the theory that vaccines cause autism—an idea widely discredited by the medical community. The pair also introduced a controversial treatment using hormone-blocking drugs, which resulted in the revocation of Mark Geier’s medical license and disciplinary actions against David Geier for practicing medicine without a license.

At a 2015 conference, Geier defended his position, claiming the scientific community dismisses their findings without proper consideration. “They think that [the vaccine's link to autism has] been completely debunked,” he said at the time.

<h4>Kennedy's Role and the Larger Context</h4>

Robert F. Kennedy Jr., a vocal critic of vaccine mandates, has clarified that Geier will not lead autism research. Instead, his focus will be on identifying any possibly overlooked or hidden data within the CDC’s database.

“There has been a lot of monkey business with the VSD,” Kennedy stated in a previous congressional appearance.

Kennedy, who once authored a now-retracted Rolling Stone article alleging a vaccine-autism cover-up, cited a 2000 CDC conference that explored preliminary data on thimerosal—a mercury-based preservative once used in vaccines. Though early findings prompted questions, later analysis confirmed no link between thimerosal and autism. Thimerosal was removed from most vaccines in 2001, and final results were published in 2003.

<h4>Exploring Autism Causes and Rising Rates</h4>

While Geier conducts his review, the U.S. Department of Health and Human Services is separately examining rising autism rates. The CDC now estimates that 1 in 31 eight-year-olds in the U.S. were diagnosed with autism in 2022. Experts attribute the increase to a combination of better diagnostic methods, genetic factors, and increased awareness.

The National Institutes of Health (NIH) also plans to fund research into other possible causes, such as environmental toxins and diet. Meanwhile, Children's Health Defense, a nonprofit formerly led by Kennedy, is hosting an online event this week centered on what it calls the “autism cover-up.”

us health news

health news

vaccines and autism

rfk hires autism critic

Dr. David Geier, a controversial orthopedic surgeon and known vaccine skeptic, is attempting to revisit long-debunked claims linking vaccines to autism. Recently hired by Health Secretary Robert F. Kennedy Jr., Geier is now reviewing historical safety data to investigate whether government agencies concealed crucial information.Accessing CDC's Vaccine Safety DatabaseGeier is reportedly seeking access to the U.S. Centers for Disease Control and Prevention’s (CDC) Vaccine Safety Datalink (VSD), a repository of vaccine safety records from millions of patients. The VSD is maintained by a dozen major healthcare systems, each controlling its own data. Full access has always been tightly controlled due to privacy and misuse concerns.Geier previously accessed the database in 2004 and 2006. However, according to The Wall Street Journal, CDC officials revoked his access both times, alleging he had misrepresented his research intentions.Despite this, Geier is once again pushing to analyze the data. It remains unclear if access has been granted. A spokesperson for the U.S. Department of Health and Human Services (HHS) stated that the department intends to take a “fresh look at all data including old data,” and emphasized that they would “follow the science—wherever it leads.”Scientific Community Raises ConcernsThe scientific and public health communities have expressed concern over Geier's involvement. “He has no record in the scientific community of doing valid work,” said Dr. Walter Orenstein, former director of the CDC’s immunization program.Geier and his late father, geneticist Mark Geier, have long promoted the theory that vaccines cause autism—an idea widely discredited by the medical community. The pair also introduced a controversial treatment using hormone-blocking drugs, which resulted in the revocation of Mark Geier’s medical license and disciplinary actions against David Geier for practicing medicine without a license.At a 2015 conference, Geier defended his position, claiming the scientific community dismisses their findings without proper consideration. “They think that [the vaccine's link to autism has] been completely debunked,” he said at the time.Kennedy's Role and the Larger ContextRobert F. Kennedy Jr., a vocal critic of vaccine mandates, has clarified that Geier will not lead autism research. Instead, his focus will be on identifying any possibly overlooked or hidden data within the CDC’s database.“There has been a lot of monkey business with the VSD,” Kennedy stated in a previous congressional appearance.Kennedy, who once authored a now-retracted Rolling Stone article alleging a vaccine-autism cover-up, cited a 2000 CDC conference that explored preliminary data on thimerosal—a mercury-based preservative once used in vaccines. Though early findings prompted questions, later analysis confirmed no link between thimerosal and autism. Thimerosal was removed from most vaccines in 2001, and final results were published in 2003.Exploring Autism Causes and Rising RatesWhile Geier conducts his review, the U.S. Department of Health and Human Services is separately examining rising autism rates. The CDC now estimates that 1 in 31 eight-year-olds in the U.S. were diagnosed with autism in 2022. Experts attribute the increase to a combination of better diagnostic methods, genetic factors, and increased awareness.The National Institutes of Health (NIH) also plans to fund research into other possible causes, such as environmental toxins and diet. Meanwhile, Children's Health Defense, a nonprofit formerly led by Kennedy, is hosting an online event this week centered on what it calls the “autism cover-up.”

rfk hires autism skeptic to look into cdc autism data

Covid-19 Active Cases Cross 7,100 In India But Signs Point To A Slowdown—How To Stay Protected Now?

India's COVID Tally Soars To Nearly 7000 Active Cases With 3 Deaths In 24 Hours; Is A New Wave Here?

india's covid tally soars to nearly 7000 active cases with 3 deaths in 24 hours; is a new wave here?

India is again facing a concerning but seemingly controlled increase in <span>Covid-19</span> cases. As of June 13, 2025, the active case count of the country is 7,131, as per the Ministry of Health and Family Welfare. Although new daily cases increased by 33 and three more deaths were added—two in Maharashtra and one in Madhya Pradesh—the overall trend indicates a potential plateau and even a slight dip, which gives optimistic hopes.

The most recent state-by-state Covid-19 dashboard published by the Ministry of Health and Family Welfare indicates remarkable regional variations in infection incidence in India. Kerala remains to have the highest burden, with 2,055 active cases, out of which 110 were new cases in one day. Gujarat is the second worst-affected state with 1,358 active cases, which saw a steep daily jump of 77 cases. Other majorly affected states are West Bengal, with 747 active cases; Delhi, with 714 cases; and Maharashtra, with 629 active infections. The Karnataka region showed a significant increase with 72 new cases, taking its active caseload to 395. On the other hand, there are no active Covid-19 cases in certain states like Arunachal Pradesh, Mizoram, and Manipur, hinting at effective containment measures. In spite of these diverse regional numbers, the overall national trend seems positively tentative. There were 1,420 new recoveries logged, elevating the total number of recovered or migrated persons to 10,976 for the year, which highlights India's resilience in its continuous Covid-19 response.

The increase is credited mainly to new Omicron sub-variants, such as JN.1, LF.7, NB.1.8.1, and XFG, which are highly contagious but produce milder symptoms than previous strains. These variants are now listed as "Variants Under Monitoring" by the World Health Organization (WHO). While not yet classified as variants of concern, they necessitate heightened vigilance, particularly among high-risk groups.

Experts advise against attributing these numbers to the onset of a full-blown wave. Rather, they refer to a seasonal surge, similar to the flu, which is consonant with the virus's post-pandemic shift towards an endemic pattern.

<h2>Why Are Booster Shots Not Recommended?</h2>

In light of India's high hybrid immunity from both vaccinations and past infections, health authorities as of now not recommending mass booster drives. Rather, targeted vaccination is being encouraged for:

<ul><li>The elderly</li><li>Immunocompromised hosts</li><li>People with chronic respiratory or cardiovascular disease</li></ul>

The Indian Medical Association and health professionals emphasize that this risk-based, strategic strategy is more effective protection than mass immunization campaigns.

Even with the recent upsurge, health workers urge not panicking but remaining proactive. Distinguishing between Covid-19 and other common seasonal viral infections—often producing the same symptoms as fever, fatigue, and cough—is now of paramount importance.

Physicians and public health specialist, point out that exhaustion from sustained lookout can precipitate complacency. We can't ignore Covid-19 as a historical moment. It's very much still around—but controlled with the appropriate preventive measures.

<h2>Actionable Tips To Prevent COVID Infection</h2>

Nowadays, personal responsibility and daily routine are still your best protection. Here's how to protect yourself:

<h4>1. Wear a Mask in Crowded Indoor Spaces</h4>

Though mandates may have disappeared, masks are effective, especially in poorly ventilated spaces indoors, on public transportation, and in medical offices.

<h4>2. Get Current with Targeted Vaccines</h4>

If you are in a high-risk group, speak with your health care provider about boosters that are available or trials soon to be under way for new variant-specific vaccines.

Prioritize a balanced diet, proper sleep, and regular physical activity in order to maintain your immune system strong against not only Covid-19 but also other flu and seasonal diseases.

Good hygiene habits such as regular handwashing, the use of sanitizers, and not touching your face while in public can significantly minimize the risk of transmission.

If you are symptomatic—or have someone living with you who is—skip gatherings and go remote work whenever possible.

Notice signs such as fever, chronic cough, body pain, fatigue, and taste/smell loss. Test early and self-isolate to avoid transmission.

Particularly if above 60 years or with underlying conditions, don't wait even for minor symptoms. Early treatment can be life-saving.

The India Covid-19 situation is serious but under control. Yes, the active cases are more than 7,100, but the recovery rates are robust, and the fatalities are few and limited to the vulnerable groups.

Instead of fear, this time it requires a recommitment to public health practices—from mask-wearing when necessary to symptom-watching and protecting the vulnerable.

<h2>Key Figures at a Glance (as of June 13, 2025)</h2>

<strong>Total Active Cases: 7,131</strong>

Top States by Active Cases: Kerala (2055), Gujarat (1358), West Bengal (747), Delhi (714), Maharashtra (629)

covid-19

india covid cases 2025

omicron subvariants

kerala covid update

covid symptoms june 2025

covid prevention tips

active covid cases india

new covid variants

India is again facing a concerning but seemingly controlled increase in Covid-19 cases. As of June 13, 2025, the active case count of the country is 7,131, as per the Ministry of Health and Family Welfare. Although new daily cases increased by 33 and three more deaths were added—two in Maharashtra and one in Madhya Pradesh—the overall trend indicates a potential plateau and even a slight dip, which gives optimistic hopes.The most recent state-by-state Covid-19 dashboard published by the Ministry of Health and Family Welfare indicates remarkable regional variations in infection incidence in India. Kerala remains to have the highest burden, with 2,055 active cases, out of which 110 were new cases in one day. Gujarat is the second worst-affected state with 1,358 active cases, which saw a steep daily jump of 77 cases. Other majorly affected states are West Bengal, with 747 active cases; Delhi, with 714 cases; and Maharashtra, with 629 active infections. The Karnataka region showed a significant increase with 72 new cases, taking its active caseload to 395. On the other hand, there are no active Covid-19 cases in certain states like Arunachal Pradesh, Mizoram, and Manipur, hinting at effective containment measures. In spite of these diverse regional numbers, the overall national trend seems positively tentative. There were 1,420 new recoveries logged, elevating the total number of recovered or migrated persons to 10,976 for the year, which highlights India's resilience in its continuous Covid-19 response.The increase is credited mainly to new Omicron sub-variants, such as JN.1, LF.7, NB.1.8.1, and XFG, which are highly contagious but produce milder symptoms than previous strains. These variants are now listed as "Variants Under Monitoring" by the World Health Organization (WHO). While not yet classified as variants of concern, they necessitate heightened vigilance, particularly among high-risk groups.Experts advise against attributing these numbers to the onset of a full-blown wave. Rather, they refer to a seasonal surge, similar to the flu, which is consonant with the virus's post-pandemic shift towards an endemic pattern.Why Are Booster Shots Not Recommended?In light of India's high hybrid immunity from both vaccinations and past infections, health authorities as of now not recommending mass booster drives. Rather, targeted vaccination is being encouraged for:The elderlyImmunocompromised hostsPeople with chronic respiratory or cardiovascular diseaseThe Indian Medical Association and health professionals emphasize that this risk-based, strategic strategy is more effective protection than mass immunization campaigns.Even with the recent upsurge, health workers urge not panicking but remaining proactive. Distinguishing between Covid-19 and other common seasonal viral infections—often producing the same symptoms as fever, fatigue, and cough—is now of paramount importance.Physicians and public health specialist, point out that exhaustion from sustained lookout can precipitate complacency. We can't ignore Covid-19 as a historical moment. It's very much still around—but controlled with the appropriate preventive measures.Actionable Tips To Prevent COVID InfectionNowadays, personal responsibility and daily routine are still your best protection. Here's how to protect yourself:1. Wear a Mask in Crowded Indoor SpacesThough mandates may have disappeared, masks are effective, especially in poorly ventilated spaces indoors, on public transportation, and in medical offices.2. Get Current with Targeted VaccinesIf you are in a high-risk group, speak with your health care provider about boosters that are available or trials soon to be under way for new variant-specific vaccines.3. Boost Your Immune SystemPrioritize a balanced diet, proper sleep, and regular physical activity in order to maintain your immune system strong against not only Covid-19 but also other flu and seasonal diseases.4. Practice HygieneGood hygiene habits such as regular handwashing, the use of sanitizers, and not touching your face while in public can significantly minimize the risk of transmission.5. Stay Away from CrowdsIf you are symptomatic—or have someone living with you who is—skip gatherings and go remote work whenever possible.6. Identify Symptoms EarlyNotice signs such as fever, chronic cough, body pain, fatigue, and taste/smell loss. Test early and self-isolate to avoid transmission.7. Seek Medical HelpParticularly if above 60 years or with underlying conditions, don't wait even for minor symptoms. Early treatment can be life-saving.The India Covid-19 situation is serious but under control. Yes, the active cases are more than 7,100, but the recovery rates are robust, and the fatalities are few and limited to the vulnerable groups.Instead of fear, this time it requires a recommitment to public health practices—from mask-wearing when necessary to symptom-watching and protecting the vulnerable.Key Figures at a Glance (as of June 13, 2025)Total Active Cases: 7,131New Cases in 24 Hours: 33Total Deaths (2025): 78Top States by Active Cases: Kerala (2055), Gujarat (1358), West Bengal (747), Delhi (714), Maharashtra (629)Recovered in 2025: 10,976 and risingDeath IN Last 24 Hours: 1 (Kerala)

covid-19 active cases cross 7,100 in india but signs point to a slowdown—how to stay protected now?

About Us

Contact Us

Terms & Conditions

Privacy Policy

Company

Health and Me is a premium website with content written and curated to function as a handbook for all Health concerns.

NHS Needs 1 Million Blood Donors To Prevent 'Red Alert' Emergency Shortage

Quick Stories

World’s First ‘Trojan Horse’ Blood Cancer Drug Rolled Out By NHS In England

RFK Hires Autism Skeptic To Look Into CDC Autism Data

Covid-19 Active Cases Cross 7,100 In India But Signs Point To A Slowdown—How To Stay Protected Now?

Health Conditions A-Z

Is It Just A Summer Cold Or The NB.1.8.1 Covid Variant? How To Tell When The Symptoms Are Nearly Identical

World’s First ‘Trojan Horse’ Blood Cancer Drug Rolled Out By NHS In England

Air India Crash May Have Triggered Flight Anxiety In Millions, Expert Shares How To Overcome Aerophobia